Asset Management One Co. Ltd. Increases Holdings in Insulet Corporation (NASDAQ:PODD)

Asset Management One Co. Ltd. boosted its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 4.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,824 shares of the medical instruments supplier's stock after purchasing an additional 1,058 shares during the period. Asset Management One Co. Ltd.'s holdings in Insulet were worth $7,307,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Horizon Investments LLC grew its holdings in Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after purchasing an additional 42 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after acquiring an additional 48 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 50 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in Insulet by 2.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock worth $566,000 after acquiring an additional 50 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Insulet by 4.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after purchasing an additional 51 shares in the last quarter.

Insider Transactions at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.39% of the company's stock.

Insulet Trading Down 4.5%

Shares of PODD traded down $14.19 during mid-day trading on Tuesday, hitting $299.99. The company had a trading volume of 1,404,448 shares, compared to its average volume of 716,587. Insulet Corporation has a 1-year low of $173.00 and a 1-year high of $329.33. The business's 50-day simple moving average is $300.32 and its 200-day simple moving average is $278.15. The stock has a market cap of $21.11 billion, a PE ratio of 53.96, a P/E/G ratio of 2.80 and a beta of 1.35. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. During the same quarter last year, the firm posted $0.73 earnings per share. Insulet's revenue was up 28.8% on a year-over-year basis. Sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PODD. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Truist Financial started coverage on Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Royal Bank Of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price objective on the stock. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Insulet has an average rating of "Moderate Buy" and a consensus target price of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.